|Dr. Sven Ante Lundberg M.D.||CEO, Pres, Principal Financial Officer & Exec. Director||986.82k||N/A||1963|
|Mr. Peter B. Silverman J.D.||Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal||614.88k||N/A||1978|
|Mr. Hui Liu Ph.D.||Chief Bus. Officer, Exec. VP & Head of Merus U.S.||611.31k||N/A||1967|
|Dr. Hennie Hoogenboom||Co-Founder and Scientific Advisor||N/A||N/A||N/A|
|Harry Shuman||Chief Accounting Officer||N/A||N/A||N/A|
|Mr. Cornelis Adriaan de Kruif Ph.D.||CTO & Exec. VP||N/A||N/A||1965|
|Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.||Chief Scientific Officer & Sr. VP||N/A||N/A||N/A|
|Ms. Jillian Connell||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Alexander Berthold Hendrik Bakker Ph.D.||Chief Devel. Officer & Exec. VP||N/A||N/A||1967|
|Dr. Andrew Joe M.D.||Chief Medical Officer & Sr. VP||N/A||N/A||1967|
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Merus N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.